In this MedPage Today video, Sayna Norouzi, MD, of the Loma Linda University Medical Center in California, offers practical ...

Sibeprenlimab gains accelerated approval from the FDA for IgA nephropathy, showing significant proteinuria reduction and ...

The FDA has granted accelerated approval to sibeprenlimab injection (Voyxact) for reducing proteinuria in adults with primary ...

Analysts at Guggenheim Partners expect Voyxact to see “broad commercial uptake” given its relatively broad label compared ...

In a rapidly heating market, Otsuka is the first to secure FDA clearance for an "anti-APRIL" therapy targeting IgA ...

Japanese drug developer Renalys Pharma yesterday announced positive top-line results from its Phase III clinical study of ...

At the American Society of Nephrology (ASN) Kidney Week meeting, an interim analysis of a phase III trial of sibeprenlimab in ...

SGLT2 inhibitors are a welcome addition to GN care, but the field is still grappling with the gap between molecular ...

Povetacicept is an investigational dual BAFF and APRIL inhibitor being tested for various glomerulonephritis types in clinical trials.

– In a Phase 3 clinical study evaluating the efficacy and safety of sparsentan in Japanese patients with IgA nephropathy (N=35), the percent change from baseline in the 24-hour urine ...